{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:47:35Z","timestamp":1781344055466,"version":"3.54.1"},"reference-count":62,"publisher":"Bentham Science Publishers Ltd.","issue":"7","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Statins are primarily used to decrease elevated LDL-cholesterol\nand thus prevent atherosclerotic cardiovascular disease. Portal hypertension is one of the\nmost important complications of chronic liver disease. Several studies indicated that\nstatins might be beneficial for portal hypertension as well but there is still no clear answer\nwhether this is true or not.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A literature search of the major databases was performed to find eligible randomized\ncontrolled trials (RCTs) analyzing the effect of statins on portal hypertension\nfrom inception to February 5th, 2021. Six RCTs with 442 patients who received statin or\nstatin plus carvedilol were finally included. Meta-analysis was performed using the Comprehensive\nMeta-Analysis V2 software.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Reduction of portal hypertension after statin treatment was not significant\n(WMD: -0.494, 95% CI: -1.239, 0.252, p=0.194; I2:0%). The reduction of portal hypertension\nwas robust in the leave-one-out sensitivity analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Treatment with statins did not decrease significantly portal hypertension.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867331666230918114451","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T04:05:42Z","timestamp":1695096342000},"page":"1323-1332","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Statins and Portal Hypertension: A Systematic Review and Meta-analysis of Randomized Controlled Trials"],"prefix":"10.2174","volume":"32","author":[{"given":"Tannaz","family":"Jamialahmadi","sequence":"first","affiliation":[{"name":"International UNESCO center for Health-Related Basic Sciences and Human Nutrition, Mashhad University\nof Medical Sciences, Mashhad, Iran"},{"name":"Applied Biomedical Research Center, Mashhad University of Medical\nSciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeljko","family":"Reiner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital Center Zagreb,\nKi\u0161pati\u0107eva 12, University of Zagreb, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam Matbou","family":"Riahi","sequence":"additional","affiliation":[{"name":"Applied Biomedical Research Center, Mashhad University of Medical\nSciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Ahmad","family":"Emami","sequence":"additional","affiliation":[{"name":"Department of Traditional Pharmacy, Mashhad University of\nMedical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Tayarani-Najaran","sequence":"additional","affiliation":[{"name":"Targeted Drug Delivery Research Center, Pharmaceutical Technology\nInstitute, Mashhad University of Medical Sciences, Mashhad, Iran"},{"name":"Medical Toxicology Research Center,\nMashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Salehabadi","sequence":"additional","affiliation":[{"name":"Applied Biomedical Research Center, Mashhad University of Medical\nSciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kesharwani","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmaceutical\nEducation and Research, Jamia Hamdard, New Delhi 110062, India"},{"name":"Department\nof Pharmacology, Center for Transdisciplinary Research, Saveetha Dental College, Saveetha Institute of\nMedical and Technical Science, Chennai 600077, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Al-Rasadi","sequence":"additional","affiliation":[{"name":"Medical Research Centre, Sultan Qaboos University, Muscat P.O.\nBox 373, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[{"name":"Applied Biomedical Research Center, Mashhad University of Medical\nSciences, Mashhad, Iran"},{"name":"Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences,\nMashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrcardio.2013.80","volume":"10","author":"Reiner \u017d.","year":"2013","unstructured":"Reiner \u017d.; Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol  2013,10(8),453-464","journal-title":"Nat Rev Cardiol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.5114\/aoms\/156147","volume":"18","author":"Banach M.","year":"2022","unstructured":"Banach M.; Reiner Z.; Cicero A.F.G.; The year in cardiovascular disease - the year of upfront lipid lowering combination therapy. Arch Med Sci  2022,18(6),1429-1434","journal-title":"Arch Med Sci"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nrd1901","volume":"4","author":"Jain M.K.","year":"2005","unstructured":"Jain M.K.; Ridker P.M.; Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov  2005,4(12),977-987","journal-title":"Nat Rev Drug Discov"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.phrs.2018.08.014","volume":"135","author":"Bahrami A.","year":"2018","unstructured":"Bahrami A.; Parsamanesh N.; Atkin S.L.; Banach M.; Sahebkar A.; Effect of statins on toll-like receptors: A new insight to pleiotropic effects. Pharmacol Res  2018,135,230-238","journal-title":"Pharmacol Res"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1901772","DOI":"10.1155\/2021\/1901772","volume":"2021","author":"Vahedian-Azimi A.","year":"2021","unstructured":"Vahedian-Azimi A.; Mohammadi S.M.; Banach M.; Improved COVID-19 outcomes following statin therapy: An updated systematic review and meta-analysis. BioMed Res Int  2021,2021,1901772","journal-title":"BioMed Res Int"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1155\/2022\/8732360","volume":"30","author":"Kandelouei T.","year":"2022","unstructured":"Kandelouei T.; Abbasifard M.; Imani D.; Aslani S.; Razi B.; Fasihi M.; Effect of statins on serum level of hs-CRP and CRP in patients with cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials. Inflammopharmacology  2022,30(2),369-383","journal-title":"Inflammopharmacology"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.5114\/aoms\/141155","volume":"17","author":"Khalifeh M.","year":"2021","unstructured":"Khalifeh M.; Penson P.; Banach M.; Sahebkar A.; Statins as anti-pyroptotic agents. Arch Med Sci  2021,17(5),1414-1417","journal-title":"Arch Med Sci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12016-020-08791-9","volume":"60","author":"Koushki K.","year":"2021","unstructured":"Koushki K.; Shahbaz S.K.; Mashayekhi K.; Sadeghi M.; Zayeri Z.D.; Taba M.Y.; Banach M.; Al-Rasadi K.; Johnston T.P.; Sahebkar A.; Anti-inflammatory action of statins in cardiovascular disease: The role of inflammasome and toll-like receptor pathways. Clin Rev Allergy Immunol  2021,60(2),175-199","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.2174\/138161209789058002","volume":"15","author":"Li H.","year":"2009","unstructured":"Li H.; F\u00f6rstermann U.; Prevention of atherosclerosis by interference with the vascular nitric oxide system. Curr Pharm Des  2009,15(27),3133-3145","journal-title":"Curr Pharm Des"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s10741-020-09929-9","volume":"26","author":"Gorabi A.M.","year":"2021","unstructured":"Gorabi A.M.; Kiaie N.; Pirro M.; Bianconi V.; Jamialahmadi T.; Sahebkar A.; Effects of statins on the biological features of mesenchymal stem cells and therapeutic implications. Heart Fail Rev  2021,26(5),1259-1272","journal-title":"Heart Fail Rev"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"101024","DOI":"10.1016\/j.arr.2020.101024","volume":"58","author":"Bahrami A.","year":"2020","unstructured":"Bahrami A.; Bo S.; Jamialahmadi T.; Sahebkar A.; Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: Molecular mechanisms. Ageing Res Rev  2020,58,101024","journal-title":"Ageing Res Rev"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"101049","DOI":"10.1016\/j.molmet.2020.101049","volume":"50","author":"Mahjoubin-Tehran M.","year":"2021","unstructured":"Mahjoubin-Tehran M.; De Vincentis A.; Mikhailidis D.P.; Atkin S.L.; Mantzoros C.S.; Jamialahmadi T.; Sahebkar A.; Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. Mol Metab  2021,50,101049","journal-title":"Mol Metab"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11745-010-3517-x","volume":"46","author":"Parizadeh S.M.R.","year":"2011","unstructured":"Parizadeh S.M.R.; Azarpazhooh M.R.; Moohebati M.; Nematy M.; Ghayour-Mobarhan M.; Tavallaie S.; Rahsepar A.A.; Amini M.; Sahebkar A.; Mohammadi M.; Ferns G.A.A.; Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. Lipids  2011,46(4),333-340","journal-title":"Lipids"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.plipres.2014.07.002","volume":"56","author":"Sahebkar A.","year":"2014","unstructured":"Sahebkar A.; Chew G.T.; Watts G.F.; Recent advances in pharmacotherapy for hypertriglyceridemia. Prog Lipid Res  2014,56(1),47-66","journal-title":"Prog Lipid Res"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.atherosclerosis.2015.05.022","volume":"241","author":"Sahebkar A.","year":"2015","unstructured":"Sahebkar A.; Kotani K.; Serban C.; Ursoniu S.; Mikhailidis D.P.; Jones S.R.; Ray K.K.; Blaha M.J.; Rysz J.; Toth P.P.; Muntner P.; Lip G.Y.H.; Banach M.; Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. Atherosclerosis  2015,241(2),433-442","journal-title":"Atherosclerosis"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1160\/TH14-11-0937","volume":"114","author":"Sahebkar A.","year":"2015","unstructured":"Sahebkar A.; Serban C.; Mikhailidis D.P.; Undas A.; Lip G.Y.H.; Muntner P.; Bittner V.; Ray K.K.; Watts G.F.; Hovingh G.K.; Rysz J.; Kastelein J.J.; Banach M.; Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thromb Haemost  2015,114(3),546-557","journal-title":"Thromb Haemost"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1160\/th15-08-0620","volume":"115","author":"Sahebkar A.","year":"2016","unstructured":"Sahebkar A.; Serban C.; Ursoniu S.; Mikhailidis D.P.; Undas A.; Lip G.Y.H.; Bittner V.; Ray K.K.; Watts G.F.; Hovingh G.K.; Rysz J.; Kastelein J.J.P.; Banach M.; The impact of statin therapy on plasma levels of von Willebrand factor antigen. Thromb Haemost  2016,115(3),520-532","journal-title":"Thromb Haemost"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"9902","DOI":"10.1038\/srep09902","volume":"5","author":"Serban C.","year":"2015","unstructured":"Serban C.; Sahebkar A.; Ursoniu S.; Mikhailidis D.P.; Rizzo M.; Lip G.Y.H.; Kees Hovingh G.; Kastelein J.J.P.; Kalinowski L.; Rysz J.; Banach M.; A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Sci Rep  2015,5(1),9902","journal-title":"Sci Rep"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.5114\/aoms.2019.89330","volume":"17","author":"Sohrevardi S.","year":"2019","unstructured":"Sohrevardi S.; Nasab F.; Mirjalili M.; Bagherniya M.; Tafti A.; Jarrahzadeh M.; Azarpazhooh M.; Saeidmanesh M.; Banach M.; Jamialahmadi T.; Sahebkar A.; Effect of atorvastatin on delirium status of patients in the intensive care unit: A randomized controlled trial. Arch Med Sci  2019,17(5),1423-1428","journal-title":"Arch Med Sci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"105986","DOI":"10.1016\/j.phrs.2021.105986","volume":"175","author":"Bland A.R.","year":"2022","unstructured":"Bland A.R.; Payne F.M.; Ashton J.C.; Jamialahmadi T.; Sahebkar A.; The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury. Pharmacol Res  2022,175,105986","journal-title":"Pharmacol Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/aoms\/149633","volume":"18","author":"Vahedian-Azimi A.","year":"2022","unstructured":"Vahedian-Azimi A.; Mannarino M.; Shojaie S.; Rahimibashar F.; Esmaeili Gouvarchin Galeh H.; Banach M.; Bianconi V.; Pirro M.; Sahebkar A.; The effect of statins on the prevalence and mortality of influenza virus infection: A systematic review and meta-analysis. Arch Med Sci  2022,18(6),1-44","journal-title":"Arch Med Sci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.3390\/jcm11061528","volume":"11","author":"Rodr\u00edguez-Miguel A.","year":"2022","unstructured":"Rodr\u00edguez-Miguel A.; Fern\u00e1ndez-Ant\u00f3n E.; Barreira-Hern\u00e1ndez D.; Garc\u00eda-Rodr\u00edguez L.A.; Gil M.; Garc\u00eda-Lled\u00f3 A.; De Abajo F.J.; Statins and colorectal cancer risk: A population-based case-control study and synthesis of the epidemiological evidence. J Clin Med  2022,11(6),1528","journal-title":"J Clin Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.5114\/aoms\/123225","volume":"18","author":"Amin F.","year":"2021","unstructured":"Amin F.; Fathi F.; Reiner \u017d.; Banach M.; Sahebkar A.; The role of statins in lung cancer. Arch Med Sci  2021,18(1),141-152","journal-title":"Arch Med Sci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","volume":"43","author":"Byty\u00e7i I.","year":"2022","unstructured":"Byty\u00e7i I.; Penson P.E.; Mikhailidis D.P.; Prevalence of statin intolerance: a meta-analysis. Eur Heart J  2022,43(34),3213-3223","journal-title":"Eur Heart J"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"100316","DOI":"10.1016\/j.jhepr.2021.100316","volume":"3","author":"Iwakiri Y.","year":"2021","unstructured":"Iwakiri Y.; Trebicka J.; Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Reports  2021,3(4),100316","journal-title":"JHEP Reports"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"104392","DOI":"10.1016\/j.ebiom.2022.104392","volume":"87","author":"Ayada I.","year":"2023","unstructured":"Ayada I.; van Kleef L.A.; Zhang H.; Liu K.; Li P.; Abozaid Y.J.; Lavrijsen M.; Janssen H.L.A.; van der Laan L.J.W.; Ghanbari M.; Peppelenbosch M.P.; Zheng M.H.; de Knegt R.J.; Pan Q.; Dissecting the multifaceted impact of statin use on fatty liver disease: A multidimensional study. EBioMedicine  2023,87,104392","journal-title":"EBioMedicine"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1053\/j.gastro.2009.01.053","volume":"136","author":"El-Serag H.B.","year":"2009","unstructured":"El-Serag H.B.; Johnson M.L.; Hachem C.; Morgana R.O.; Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology  2009,136(5),1601-1608","journal-title":"Gastroenterology"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1053\/j.gastro.2019.01.026","volume":"156","author":"Kaplan D.E.","year":"2019","unstructured":"Kaplan D.E.; Serper M.A.; Mehta R.; Fox R.; John B.; Aytaman A.; Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis. Gastroenterology  2019,156(6),1693-1706","journal-title":"Gastroenterology"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/apt.12430","volume":"38","author":"Motzkus-Feagans C.","year":"2013","unstructured":"Motzkus-Feagans C.; Pakyz A.L.; Ratliff S.M.; Bajaj J.S.; Lapane K.L.; Statin use and infections in veterans with cirrhosis. Aliment Pharmacol Ther  2013,38(6),611-618","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","volume":"150","author":"Mohanty A.","year":"2016","unstructured":"Mohanty A.; Tate J.P.; Garcia-Tsao G.; Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C\u2013related compensated cirrhosis. Gastroenterology  2016,150(2),430-440","journal-title":"Gastroenterology"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","volume":"150","author":"Abraldes J.G.","year":"2016","unstructured":"Abraldes J.G.; Villanueva C.; Aracil C.; Turnes J.; Hernandez-Guerra M.; Genesca J.; Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology  2016,150(5),1160-1170","journal-title":"Gastroenterology"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1007\/s10620-014-3179-2","volume":"59","author":"Kumar S.","year":"2014","unstructured":"Kumar S.; Grace N.D.; Qamar A.A.; Statin use in patients with cirrhosis: A retrospective cohort study. Dig Dis Sci  2014,59(8),1958-1965","journal-title":"Dig Dis Sci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/hep.29172","volume":"66","author":"Chang F.M.","year":"2017","unstructured":"Chang F.M.; Wang Y.P.; Lang H.C.; Tsai C.F.; Hou M.C.; Lee F.Y.; Lu C.L.; Statins decrease the risk of decompensation in hepatitis B virus\u2013 and hepatitis C virus\u2013related cirrhosis: A population\u2010based study. Hepatology  2017,66(3),896-907","journal-title":"Hepatology"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/bcpt.12844","volume":"122","author":"Stokkeland K.","year":"2018","unstructured":"Stokkeland K.; Lageborn C.T.; Ekbom A.; H\u00f6ijer J.; Bottai M.; St\u00e5l P.; S\u00f6derberg-L\u00f6fdal K.; Statins and angiotensin\u2010converting enzyme inhibitors are associated with reduced mortality and morbidity in chronic liver disease. Basic Clin Pharmacol Toxicol  2018,122(1),104-110","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cld.2013.12.001","volume":"18","author":"Iwakiri Y.","year":"2014","unstructured":"Iwakiri Y.; Pathophysiology of portal hypertension. Clin Liver Dis  2014,18(2),281-291","journal-title":"Clin Liver Dis"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","volume":"126","author":"Zafra C.","year":"2004","unstructured":"Zafra C.; Abraldes J.G.; Turnes J.; Berzigotti A.; Fern\u00e1ndez M.; Garc\u00eda-Pag\u00e1n J.C.; Rod\u00e9s J.; Bosch J.; Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology  2004,126(3),749-755","journal-title":"Gastroenterology"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"10372","DOI":"10.3390\/ijms221910372","volume":"22","author":"Kreisel W.","year":"2021","unstructured":"Kreisel W.; Lazaro A.; Trebicka J.; Grosse Perdekamp M.; Schmitt-Graeff A.; Deibert P.; Cyclic GMP in liver cirrhosis\u2014role in pathophysiology of portal hypertension and therapeutic implications. Int J Mol Sci  2021,22(19),10372","journal-title":"Int J Mol Sci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S0016-5085(98)70487-1","volume":"114","author":"Rockey D.C.","year":"1998","unstructured":"Rockey D.C.; Chung J.J.; Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: Endothelial dysfunction in portal hypertension. Gastroenterology  1998,114(2),344-351","journal-title":"Gastroenterology"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1053\/j.gastro.2018.07.022","volume":"155","author":"Tripathi D.M.","year":"2018","unstructured":"Tripathi D.M.; Vilaseca M.; Lafoz E.; Garcia-Calder\u00f3 H.; Viegas Haute G.; Fern\u00e1ndez-Iglesias A.; Rodrigues de Oliveira J.; Garc\u00eda-Pag\u00e1n J.C.; Bosch J.; Gracia-Sancho J.; Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension. Gastroenterology  2018,155(5),1564-1577","journal-title":"Gastroenterology"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1136\/gutjnl-2019-318237","volume":"69","author":"Bosch J.","year":"2020","unstructured":"Bosch J.; Gracia-Sancho J.; Abraldes J.G.; Cirrhosis as new indication for statins. Gut  2020,69(5),953-962","journal-title":"Gut"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"106367","DOI":"10.1016\/j.cct.2021.106367","volume":"104","author":"Kaplan D.E.","year":"2021","unstructured":"Kaplan D.E.; Mehta R.; Garcia-Tsao G.; Albrecht J.; Aytaman A.; Baffy G.; Bajaj J.; Hernaez R.; Hunt K.; Ioannou G.; Johnson K.; Kanwal F.; Lee T.H.; Monto A.; Pandya P.; Schaubel D.; Taddei T.H.; SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing events of decompensation. Contemp Clin Trials  2021,104,106367","journal-title":"Contemp Clin Trials"},{"key":"ref=42","author":"Higgins J.P.T.G.S.","year":"2009","unstructured":"Higgins J.P.T.G.S.;  Handbook for systematic reviews of interventions version  2009","journal-title":"Handbook for systematic reviews of interventions version"},{"key":"ref=43","author":"Borenstein M.","year":"2005","unstructured":"Borenstein M.; Hedges L.; Higgins J.; Rothstein H.;  Comprehensive meta-analysis, version 2 biostat  2005","journal-title":"Comprehensive meta-analysis, version 2 biostat"},{"key":"ref=44","author":"Sutton A.J.","year":"2000","unstructured":"Sutton A.J.; Abrams K.R.; Jones D.R.; Jones D.R.; Sheldon T.A.; Song F.; Methods for meta-analysis in medical research Wiley Chichester.  2000"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"Hozo S.P.","year":"2005","unstructured":"Hozo S.P.; Djulbegovic B.; Hozo I.; Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol  2005,5(1),13","journal-title":"BMC Med Res Methodol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.plipres.2015.08.003","volume":"60","author":"Ferretti G.","year":"2015","unstructured":"Ferretti G.; Bacchetti T.; Sahebkar A.; Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials. Prog Lipid Res  2015,60,50-73","journal-title":"Prog Lipid Res"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.phrs.2015.07.008","volume":"99","author":"Banach M.","year":"2015","unstructured":"Banach M.; Serban C.; Ursoniu S.; Rysz J.; Muntner P.; Toth P.P.; Jones S.R.; Rizzo M.; Glasser S.P.; Watts G.F.; Blumenthal R.S.; Lip G.Y.H.; Mikhailidis D.P.; Sahebkar A.; Statin therapy and plasma coenzyme Q10 concentrations\u2014A systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res  2015,99,329-336","journal-title":"Pharmacol Res"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","volume":"136","author":"Abraldes J.G.","year":"2009","unstructured":"Abraldes J.G.; Albillos A.; Ba\u00f1ares R.; Turnes J.; Gonz\u00e1lez R.; Garc\u00eda-Pag\u00e1n J.C.; Bosch J.; Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: A randomized controlled trial. Gastroenterology  2009,136(5),1651-1658","journal-title":"Gastroenterology"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","volume":"47","author":"Pollo-Flores P.","year":"2015","unstructured":"Pollo-Flores P.; Soldan M.; Santos U.C.; Kunz D.G.; Mattos D.E.; da Silva A.C.; Marchiori R.C.; Rezende G.F.M.; Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial. Dig Liver Dis  2015,47(11),957-963","journal-title":"Dig Liver Dis"},{"key":"ref=50","author":"Choudhary R.V.A.","year":"2016","unstructured":"Choudhary R.V.A.; Jindal A.; Kumar G.; Sarin S.K.; Addition of simvastatin to carvedilol does not improve hemodynamic response in cirrhotics with varices without prior bleed: Preliminary results of an open label RCT. In:  2016"},{"key":"ref=51","author":"Alvarado-Tapias E.","year":"2016","unstructured":"Alvarado-Tapias E.; Ardevol A.; Pavel O.; Montanes R.; Murzi M.; Oblitas Susanibar E.;  Eds; Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with portal hypertension and no-response to beta-blockers: a doubleblind randomized trial; Alvarado-Tapias, E; Ardevol, A; Pavel, O; Montanes, R; Murzi, M; Oblitas Susanibar, E, Eds; Hepatology; Wiley-blackwell 111 river st: Hoboken 07030-5774, nj USA,  2016","journal-title":"Eds; Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with portal hypertension and no-response to beta-blockers: a doubleblind randomized trial; Alvarado-Tapias, E; Ardevol, A; Pavel, O; Montanes, R; Murzi, M; Oblitas Susanibar, E, Eds; Hepatology; Wiley-blackwell 111 river st: Hoboken 07030-5774, nj USA,"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/MEG.0000000000001006","volume":"30","author":"Bishnu S.","year":"2018","unstructured":"Bishnu S.; Ahammed S.M.; Sarkar A.; Hembram J.; Chatterjee S.; Das K.; Dhali G.K.; Chowdhury A.; Das K.; Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension. Eur J Gastroenterol Hepatol  2018,30(1),54-59","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"729","DOI":"10.14309\/ajg.0000000000000551","volume":"115","author":"Vijayaraghavan R.","year":"2020","unstructured":"Vijayaraghavan R.; Jindal A.; Arora V.; Choudhary A.; Kumar G.; Sarin S.K.; Hemodynamic effects of adding simvastatin to carvedilol for primary prophylaxis of variceal bleeding: A randomized controlled trial. Am J Gastroenterol  2020,115(5),729-737","journal-title":"Am J Gastroenterol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s11938-018-0180-4","volume":"16","author":"Moctezuma-Vel\u00e1zquez C.","year":"2018","unstructured":"Moctezuma-Vel\u00e1zquez C.; Abraldes J.G.; Montano-Loza A.J.; The use of statins in patients with chronic liver disease and cirrhosis. Curr Treat Options Gastroenterol  2018,16(2),226-240","journal-title":"Curr Treat Options Gastroenterol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"011510","DOI":"10.1002\/14651858.CD011510.pub2","volume":"10","author":"Zacharias A.P.","year":"2018","unstructured":"Zacharias A.P.; Jeyaraj R.; Hobolth L.; Bendtsen F.; Gluud L.L.; Morgan M.Y.; Carvedilol versus traditional, non\u2010selective beta\u2010blockers for adults with cirrhosis and gastroesophageal varices. Cochrane Database Syst Rev  2018,10(10),011510","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1056\/NEJM198710013171403","volume":"317","author":"Pascal J.P.","year":"1987","unstructured":"Pascal J.P.; Cales P.; Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med  1987,317(14),856-861","journal-title":"N Engl J Med"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"e030038","DOI":"10.1136\/bmjopen-2019-030038","volume":"9","author":"Wan S.","year":"2019","unstructured":"Wan S.; Huang C.; Zhu X.; Systematic review with a meta-analysis: Clinical effects of statins on the reduction of portal hypertension and variceal haemorrhage in cirrhotic patients. BMJ Open  2019,9(7),e030038","journal-title":"BMJ Open"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/hep.21673","volume":"46","author":"Trebicka J.","year":"2007","unstructured":"Trebicka J.; Hennenberg M.; Laleman W.; Shelest N.; Biecker E.; Schepke M.; Nevens F.; Sauerbruch T.; Heller J.; Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology  2007,46(1),242-253","journal-title":"Hepatology"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1136\/gutjnl-2014-308338","volume":"64","author":"Marrone G.","year":"2015","unstructured":"Marrone G.; Maeso-D\u00edaz R.; Garc\u00eda-Cardena G.; Abraldes J.G.; Garc\u00eda-Pag\u00e1n J.C.; Bosch J.; Gracia-Sancho J.; KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: Behind the molecular mechanisms of statins. Gut  2015,64(9),1434-1443","journal-title":"Gut"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1136\/gutjnl-2014-308800","volume":"64","author":"Trebicka J.","year":"2015","unstructured":"Trebicka J.; Schierwagen R.; Statins, Rho GTPases and KLF2: New mechanistic insight into liver fibrosis and portal hypertension. Gut  2015,64(9),1349-1350","journal-title":"Gut"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jhep.2010.04.025","volume":"53","author":"Trebicka J.","year":"2010","unstructured":"Trebicka J.; Hennenberg M.; Odenthal M.; Shir K.; Klein S.; Granzow M.; Vogt A.; Dienes H.P.; Lammert F.; Reichen J.; Heller J.; Sauerbruch T.; Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol  2010,53(4),702-712","journal-title":"J Hepatol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jhep.2012.08.026","volume":"58","author":"Marrone G.","year":"2013","unstructured":"Marrone G.; Russo L.; Rosado E.; Hide D.; Garc\u00eda-Carde\u00f1a G.; Garc\u00eda-Pag\u00e1n J.C.; Bosch J.; Gracia-Sancho J.; The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial\u2013stellate cell deactivation induced by statins. J Hepatol  2013,58(1),98-103","journal-title":"J Hepatol"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867331666230918114451","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/221202\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867331666230918114451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T06:06:22Z","timestamp":1741241182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/221202\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":62,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867331666230918114451","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-01-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}